Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRXrttnews·2 days ago, 03:38 AMSLN-3.76%FBRX-8.24%
Forte Biosciences, Inc. (NASDAQ:FBRX) Receives Consensus Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 21 at 05:14 AMFBRX-8.24%BAC+1.26%
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & Morerttnews·Jul 19 at 12:05 PMAMRX-0.28%PSNL-3.60%
Is Forte Biosciences (FBRX) Fully Valued Following Its Positive FB102 Vitiligo Data?Simplywall·Jul 19 at 04:03 AMFBRX-8.24%
US Niche Equities Post Robust Q1 2026 Growth Amid Broadening Market BreadthGlobal Report·Jul 15 at 04:14 AMANF+3.21%ADDYY+1.56%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jul 10 at 12:05 PMVTAK-35.52%VRAX0.00%
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable ImprovementMarket Beat·Jul 10 at 09:02 AMFBRX-8.24%
Pre-market hot trades in US stocks: Sandisk pre-market down 3.85%; Forte Biosciences pre-market up 3.40%Price Alert·Jul 10 at 03:57 AMSNDK-10.79%FBRX-8.24%
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watchrttnews·Jul 9 at 09:55 PMFBRX-8.24%CNTB-2.73%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 9 at 12:05 PMVRAX0.00%IONS+1.22%
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Studybenzinga_article·Jul 9 at 11:26 AMFBRX-8.24%
Forte Bio surges on early-stage trial data for vitiligo therapybusinessinsider·Jul 9 at 10:26 AMFBRX-8.24%
Forte Biosciences shares are trading higher after the company announced results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo.benzinga_article·Jul 9 at 09:38 AMFBRX-8.24%
